Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cellegy testosterone gel completes phase II trial

Sep. 9, 1999

Favorable pharmacokinetics and pharmacodynamics reported for insulin aspart at FIP '99

Sep. 8, 1999

Novel pyridine and pyrimidine derivatives from Amgen particularly useful for obesity Rx

Sep. 8, 1999

Dr. Reddy performs SAR studies in the area of antidiabetic/hypolipidemic thiazolidinediones

Sep. 7, 1999

PTP1B inhibitors evaluated at Wyeth-Ayerst for potential as oral antidiabetic agents

Sep. 6, 1999

Regeneron provides interim data from phase I Axokine study and highlights further plans

Sep. 6, 1999

OSI establishes partnership with Tanabe Seiyaku for diabetes treatment

Sep. 6, 1999

Genzyme General and Genovo to collaborate on gene therapy for rare genetic diseases

Sep. 6, 1999

Exocell receives patents for diabetic kidney disease therapy

Sep. 3, 1999

Hemopure receives fast track status in South Africa

Sep. 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...